PI’s: Peter Pang, MD Phillip Levy, MD and Sean Collins, MD
Collecting ED data about patients with AHF and sharing it with others supports the development of new diagnostic, therapeutic and disposition decision making pathways. Further, biomarker exploration may lead to safe, innovative, and effective new medicines and diagnostics to address healthcare needs, improve medical care, and promote and improve public health. The objective of the EMROC registry is to create a repository of ED patients who present in the exacerbation phase of their disease. We have enrolled 100’s of patients at our centers to create this comprehensive ED-based registry.
Our Specific Aims are to:
- Collect demographic data from subjects to enable investigation of patient characteristics, diagnostic testing and treatment and disposition decisions.
- Collect blood samples to process, freeze and store for future investigation.
- Determine outcomes at 30-, 90-, and 180-days after the ED visit